Conference Reports for NATAP

62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back

Antiviral Activity and Safety of INX-08189, a Nucleotide Polymerase Inhibitor, Following 7-Days of Oral Therapy in Naïve Genotype-1 HCV Patients       Reported by Jules Levin AASLD Nov 5-9 2011 San Francisco   M Rodriguez-Torres1, E Lawitz2, L Hazan3, A Barry4, E Wenzel4, J Alam5, G Henson4, J Patti4 1Fundación de Investigación, San Juan, PR; 2Alamo Medical Research, Ltd. San Antonio, TX; 3Axis Clinical Trials, Los Angeles, CA; 5Sanofi Aventis, Paris, France; 4Inhibitex, Inc., Alpharetta, GA